US Broker Ratings

Precigen, Inc. (PGEN) Stock Analysis: Exploring a Potential 283% Upside with Innovative Biotech Solutions

For investors looking to dive into the dynamic world of biotechnology, Precigen, Inc. (NASDAQ: PGEN) presents a compelling opportunity with its groundbreaking gene and cell therapy solutions. With a market..

Tilray Brands, Inc. (TLRY): Investor Outlook on a Potential 48.61% Upside in the Cannabis Sector

Tilray Brands, Inc. (NASDAQ: TLRY), a prominent player in the healthcare sector under the umbrella of drug manufacturers specializing in specialty and generic products, is attracting investor interest with its..

AngioDynamics, Inc. (ANGO) Stock Analysis: A 71.97% Potential Upside Ignites Investor Interest

AngioDynamics, Inc. (ANGO), a notable player in the healthcare sector, is positioning itself as a compelling opportunity for investors, especially amidst the promising analyst ratings that suggest a potential upside..

Surmodics, Inc. (SRDX) Stock Analysis: Navigating Challenges with Strategic Growth in the Medical Devices Sector

Surmodics, Inc. (NASDAQ: SRDX), a significant player in the healthcare sector specializing in medical devices, presents a unique profile for investors seeking to navigate the complexities of the healthcare market...

MBX Biosciences, Inc. (MBX) Stock Analysis: Potential 187.80% Upside in Biotech Innovation

MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company, is capturing investor attention with a compelling potential upside of 187.80%. Specializing in the discovery and development of precision peptide therapies,..

Definitive Healthcare Corp. (DH) Stock Analysis: Navigating a Complex Healthcare Landscape with a 2.5% Upside

Definitive Healthcare Corp. (NASDAQ: DH), a prominent player in the Health Information Services industry, has carved out a niche by providing an advanced software-as-a-service (SaaS) healthcare commercial intelligence platform. Headquartered..

Emergent BioSolutions Inc. (EBS) Investor Outlook: An 80% Upside Potential Amidst Market Volatility

Emergent BioSolutions Inc. (NYSE: EBS) presents an intriguing opportunity for investors navigating the healthcare sector, particularly within the specialty and generic drug manufacturing space. With a market capitalization of $405.46..

Septerna, Inc. (SEPN) Stock Analysis: Unveiling a Promising 78.83% Upside Potential in Biotechnology

Septerna, Inc. (NASDAQ: SEPN), a burgeoning player in the biotechnology sector, is drawing significant attention within the investor community. This clinical-stage company, with a market capitalization of $604.21 million, is..

Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: A Biotech Gem with 222% Potential Upside

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) emerges as a compelling player in the biotechnology sector, particularly for investors seeking high-growth opportunities within the healthcare space. With a market capitalization of $491.59..

Regulus Therapeutics Inc. (RGLS) Stock Analysis: Navigating the Biotechnology Sector with a -14.22% Potential Downside

Regulus Therapeutics Inc. (NASDAQ: RGLS), a biotechnology company dedicated to the development of innovative treatments for genetically-based orphan diseases, is a company that might intrigue investors looking for opportunities in..

Verve Therapeutics, Inc. (VERV) Stock Analysis: Unveiling a 35.74% Potential Upside in the Biotechnology Market

Verve Therapeutics, Inc. (NASDAQ: VERV) is capturing attention within the biotechnology sector for its innovative approach to tackling cardiovascular disease through gene editing. With a market capitalization of approximately $994.04..

Mind Medicine (MindMed) Inc. (MNMD) Stock Analysis: Exploring a Robust 152% Potential Upside

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has recently captured the attention of investors with its remarkable potential upside of 152.06%. As a clinical-stage biopharmaceutical company, MindMed is pioneering innovative treatments..

Capricor Therapeutics, Inc. (CAPR): Investor Outlook on a Biotech Stock with a 217.90% Upside

For investors seeking high-growth potential in the biotechnology sector, Capricor Therapeutics, Inc. (NASDAQ: CAPR) presents an intriguing opportunity. With a current market capitalization of approximately $296.19 million, this clinical-stage biotech..

Inventiva S.A. (IVA) Stock Analysis: Unveiling a 221% Potential Upside in Biotech Innovation

Investors navigating the complex world of biotechnology stocks may find a compelling opportunity in Inventiva S.A. – American Depositary Shares (IVA), a company that has captured attention with its potential..

Maze Therapeutics, Inc. (MAZE): A Biotech Stock with a 53% Potential Upside

Maze Therapeutics, Inc. (NASDAQ: MAZE) has captured the attention of investors with its promising biotechnology endeavors and a potential upside of 53.19%, as indicated by analyst ratings. This clinical-stage biopharmaceutical..

Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring a 47% Upside Potential

Investors seeking opportunities in the healthcare sector might find Organogenesis Holdings Inc. (NASDAQ: ORGO) an intriguing prospect, especially given its recent price performance and the substantial upside potential analysts have..

Orthofix Medical Inc. (OFIX) Stock Analysis: Eyeing a 98.40% Potential Upside in the Medical Devices Sector

Orthofix Medical Inc. (NASDAQ: OFIX), a key player in the healthcare sector specializing in medical devices, finds itself at a pivotal moment that could present significant opportunities for investors. With..

Verastem, Inc. (VSTM) Stock Analysis: A 188% Upside Potential in Biotech Innovation

Verastem, Inc. (NASDAQ: VSTM) presents a compelling opportunity in the biotech sector with its focus on innovative cancer treatments. Despite the recent price dip, the company’s strategic initiatives and robust..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a 58% Upside Potential Amid Strong Buy Ratings

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) has emerged as a beacon of interest for investors in the biotechnology sector, showcasing a compelling 58.10% potential upside based on current analyst ratings. As..

Kamada Ltd. (KMDA): Investor Outlook with 89.59% Potential Upside

Kamada Ltd. (NASDAQ: KMDA), an Israeli healthcare company specializing in the development of plasma-derived protein therapeutics, is attracting significant investor attention. With a market capitalization of $456.13 million, Kamada operates..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds